Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia
Synlogic, Inc. (SYBX)
Last synlogic, inc. earnings: 3/12 04:19 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.synlogictx.com/news-and-events/news-releases
Company Research
Source: Business Wire
– SYNB1020 well tolerated in Phase 1b/2a study, but did not lower blood ammonia in patients with cirrhosis –– Company will focus resources on advancement of SYNB1618, SYNB1891 and new early development programs – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic, Inc., (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced that it is discontinuing development of SYNB1020, an early stage clinical product candidate for the treatment of hyperammonemia. The decision to discontinue the program was based on top-line data from an interim analysis of a randomized, double-blind, placebo-controlled Phase 1b/2a study of the Synthetic Biotic medicine in 23 patients with cirrhosis and elevated blood ammonia. The study was designed to evaluate the safety and tolerability of SYNB1020 treatment, as well as changes in blood ammonia levels and several exploratory endpoints associated with early stage hepatic encephalop
Show less
Read more
Impact Snapshot
Event Time:
SYBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYBX alerts
High impacting Synlogic, Inc. news events
Weekly update
A roundup of the hottest topics
SYBX
News
- Synlogic, Inc. (NASDAQ: SYBX) was upgraded by analysts at HC Wainwright from a "sell" rating to a "neutral" rating.MarketBeat
- Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Synlogic Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire
- Synlogic Adopts Limited Duration Stockholders Rights Plan [Yahoo! Finance]Yahoo! Finance
- Synlogic Adopts Limited Duration Stockholders Rights PlanGlobeNewswire
SYBX
Earnings
- 11/9/23 - Miss
SYBX
Sec Filings
- 4/22/24 - Form 144
- 4/18/24 - Form SC
- 4/4/24 - Form 4
- SYBX's page on the SEC website